Immunogenomic Biomarkers and Validation in Lynch Syndrome
Ramadhani Chambuso,
Mbali Mthembu,
Eveline Kaambo,
Barbara Robertson,
Raj Ramesar
Affiliations
Ramadhani Chambuso
MRC Unit for Genomic and Precision Medicine, Division of Human Genetics, Department of Pathology, Institute for Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7704, South Africa
Mbali Mthembu
MRC Unit for Genomic and Precision Medicine, Division of Human Genetics, Department of Pathology, Institute for Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7704, South Africa
Eveline Kaambo
Department of Biochemistry and Medical Microbiology, School of Medicine, University of Namibia, 340, Windhoek 9000, Namibia
Barbara Robertson
Department of Radiation Oncology, Groote Schuur Hospital, University of Cape Town, Observatory, Cape Town 7704, South Africa
Raj Ramesar
MRC Unit for Genomic and Precision Medicine, Division of Human Genetics, Department of Pathology, Institute for Infectious Diseases and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town 7704, South Africa
Lynch syndrome (LS) is an inherited disorder in which affected individuals have a significantly higher-than-average risk of developing colorectal and non-colorectal cancers, often before the age of 50 years. In LS, mutations in DNA repair genes lead to a dysfunctional post-replication repair system. As a result, the unrepaired errors in coding regions of the genome produce novel proteins, called neoantigens. Neoantigens are recognised by the immune system as foreign and trigger an immune response. Due to the invasive nature of cancer screening tests, universal cancer screening guidelines unique for LS (primarily colonoscopy) are poorly adhered to by LS variant heterozygotes (LSVH). Currently, it is unclear whether immunogenomic components produced as a result of neoantigen formation can be used as novel biomarkers in LS. We hypothesise that: (i) LSVH produce measurable and dynamic immunogenomic components in blood, and (ii) these quantifiable immunogenomic components correlate with cancer onset and stage. Here, we discuss the feasibility to: (a) identify personalised novel immunogenomic biomarkers and (b) validate these biomarkers in various clinical scenarios in LSVH.
